Kinney Horn has over twenty years of experience in life science finance, leadership, operations, and biopharmaceutical Business Development roles, representing over $30B in transactions. Prior to joining Immunome, Mr. Horn was Chief Business Officer of Olema Oncology, where he was part of the team that completed the company’s $85M Series C crossover financing round and $240M IPO. Before Olema, he was an Entrepreneur in Residence at EcoR1 Capital.
Mr. Horn spent 16 years at Genentech, where his transaction experience included leading teams from of up to 50 employees in identifying pre-clinical and clinical stage opportunities, structuring strategic alliances, negotiating and closing deals, and managing contractual relationships. His international experience includes negotiations with European and Asian companies. In addition to corporate transaction responsibilities, he led the annual oncology strategic sourcing process for 13 areas of oncology research and development.
Prior to Roche’s acquisition of Genentech, Mr. Horn worked with early-stage biotechnology companies that Genentech had invested in through GenenFUND, Genentech’s private equity fund; and began his career in various investment banking and venture roles. Mr. Horn has degrees in economics, international affairs and biochemistry from Mary Washington College and Georgetown University.
What is Kinney Horn's net worth?
The estimated net worth of Kinney Horn is at least $1.41 million as of August 4th, 2026. Mr. Horn owns 50,366 shares of Immunome stock worth more than $1,409,744 as of August 12th. This net worth approximation does not reflect any other investments that Mr. Horn may own. Learn More about Kinney Horn's net worth.
How do I contact Kinney Horn?
Has Kinney Horn been buying or selling shares of Immunome?
In the last ninety days, Kinney Horn has sold $2,300,855.44 in Immunome stock. Most recently, Kinney Horn sold 90,616 shares of the business's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $25.09, for a transaction totalling $2,273,555.44. Following the completion of the sale, the insider now directly owns 50,366 shares of the company's stock, valued at $1,263,682.94. Learn More on Kinney Horn's trading history.
Who are Immunome's active insiders?
Immunome's insider roster includes Isaac Barchas (Director), Jean Bienaime (Director), Jack Higgins (Insider), Kinney Horn (Chief Business Officer), Robert Lechleider (Insider), Michael Lefenfeld (Director), Michael Rapp (Director), Max Rosett (CFO), Purnanand Sarma (CEO), Clay Siegall (CEO), Philip Tsai (CTO), Bruce Turner (Insider), and Philip Wagenheim (Director). Learn More on Immunome's active insiders.
Are insiders buying or selling shares of Immunome?
In the last twelve months, Immunome insiders bought shares 7 times. They purchased a total of 85,018 shares worth more than $1,783,233.29. In the last twelve months, insiders at the sold shares 19 times. They sold a total of 1,204,948 shares worth more than $26,970,998.26. The most recent insider tranaction occured on August, 12th when Director Isaac Barchas sold 11,048 shares worth more than $301,058.00. Insiders at Immunome own 7.2% of the company.
Learn More about insider trades at Immunome. Information on this page was last updated on 8/12/2026.
